Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Pediatric drug regulation: International perspectives.

Baum VC, Bax R, Heon D, Yang Z, Sakiyama M.

Paediatr Anaesth. 2019 Jun;29(6):572-582. doi: 10.1111/pan.13638. Epub 2019 Apr 14.

PMID:
30924233
2.

Enrollment of Neonates in More Than One Clinical Trial.

Davis JM, Baer GR, Portman R, Nelson R, Storari L, Aranda JV, Bax R, Zajicek A, Klein A, Turner M, Baygani S, Thomson M, Allegaert K; International Neonatal Consortium.

Clin Ther. 2017 Oct;39(10):1959-1969. doi: 10.1016/j.clinthera.2017.09.006. Epub 2017 Oct 4. Review.

3.

The International Neonatal Consortium: collaborating to advance regulatory science for neonates.

Turner MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson LD.

Pediatr Res. 2016 Oct;80(4):462-4. doi: 10.1038/pr.2016.119. Epub 2016 Jun 8. No abstract available.

PMID:
27384407
4.

Alternatives to antibiotics-a pipeline portfolio review.

Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH.

Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Review.

PMID:
26795692
5.

Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014.

Offringa M, Davis JM, Turner MA, Ward R, Bax R, Maldonado S, Sinha V, McCune SK, Zajicek A, Benjamin DK Jr, Bucci-Rechtweg C, Nelson RM.

Ther Innov Regul Sci. 2015 Sep;49(5):623-631. doi: 10.1177/2168479015597730.

PMID:
30227031
6.

Neonatal medicines research: challenges and opportunities.

Samardzic J, Turner MA, Bax R, Allegaert K.

Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1041-52. doi: 10.1517/17425255.2015.1046433. Epub 2015 May 10. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2015;11(8):1169.

PMID:
25958820
7.

Antibiotics: the changing regulatory and pharmaceutical industry paradigm.

Bax R, Green S.

J Antimicrob Chemother. 2015 May;70(5):1281-4. doi: 10.1093/jac/dku572. Epub 2015 Jan 28. Review.

PMID:
25634991
8.

Introduction to antibiotic resistance.

Bax R, Griffin D.

Handb Exp Pharmacol. 2012;(211):1-12. doi: 10.1007/978-3-642-28951-4_1.

PMID:
23090592
9.

Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects.

Coates T, Bax R, Coates A.

J Antimicrob Chemother. 2009 Jul;64(1):9-15. doi: 10.1093/jac/dkp159. Epub 2009 May 18. Review.

10.

Challenges in developing new antibacterial drugs.

Williams KJ, Bax RP.

Curr Opin Investig Drugs. 2009 Feb;10(2):157-63. Review.

PMID:
19197793
11.

Development of a twice daily dosing regimen of amoxicillin/clavulanate.

Bax R.

Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S118-21. Epub 2007 Nov 5. Review.

PMID:
17983732
12.

Slx9p facilitates efficient ITS1 processing of pre-rRNA in Saccharomyces cerevisiae.

Bax R, Raué HA, Vos JC.

RNA. 2006 Nov;12(11):2005-13. Epub 2006 Oct 3.

13.
14.

Congenital cataract, muscular hypotonia, developmental delay and sensorineural hearing loss associated with a defect in copper metabolism.

Horváth R, Freisinger P, Rubio R, Merl T, Bax R, Mayr JA, Shawan, Müller-Höcker J, Pongratz D, Moller LB, Horn N, Jaksch M.

J Inherit Metab Dis. 2005;28(4):479-92.

PMID:
15902551
15.

U3 snoRNP and Rrp5p associate independently with Saccharomyces cerevisiae 35S pre-rRNA, but Rrp5p is essential for association of Rok1p.

Vos HR, Bax R, Faber AW, Vos JC, Raué HA.

Nucleic Acids Res. 2004 Nov 2;32(19):5827-33. Print 2004.

16.

A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.

Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R.

Contraception. 2004 Sep;70(3):233-40.

PMID:
15325893
17.

A phase I comparative postcoital testing study of three concentrations of C31G.

Mauck CK, Creinin MD, Barnhart KT, Ballagh SA, Archer DF, Callahan MM, Schmitz SW, Bax R.

Contraception. 2004 Sep;70(3):227-31.

PMID:
15325892
18.

Male tolerance study of 1% C31G.

Mauck CK, Frezieres RG, Walsh TL, Schmitz SW, Callahan MM, Bax R.

Contraception. 2004 Sep;70(3):221-5.

PMID:
15325891
19.

Microbicides--evaluating multiple formulations of C31G.

Bax R, Douville K, McCormick D, Rosenberg M, Higgins J, Bowden M.

Contraception. 2002 Nov;66(5):365-8.

PMID:
12443968
20.

The future challenges facing the development of new antimicrobial drugs.

Coates A, Hu Y, Bax R, Page C.

Nat Rev Drug Discov. 2002 Nov;1(11):895-910. Review.

PMID:
12415249
21.
22.

Surveillance of antimicrobial resistance--what, how and whither?

Bax R, Bywater R, Cornaglia G, Goossens H, Hunter P, Isham V, Jarlier V, Jones R, Phillips I, Sahm D, Senn S, Struelens M, Taylor D, White A.

Clin Microbiol Infect. 2001 Jun;7(6):316-25. Review.

23.

The millennium bugs--the need for and development of new antibacterials.

Bax R, Mullan N, Verhoef J.

Int J Antimicrob Agents. 2000 Sep;16(1):51-9. Review.

PMID:
11185414
24.

Antibiotic clinical trials revisited.

Baquero F, Bax R, Phillips I.

J Antimicrob Chemother. 2000 Nov;46(5):651-2. No abstract available.

PMID:
11062182
25.

Self-medication of antibacterials without prescription (also called 'over-the-counter' use). A report of a Working Party of the British Society for Antimicrobial Chemotherapy.

Reeves DS, Finch RG, Bax RP, Davey PG, Po AL, Lingam G, Mann SG, Pringle MA.

J Antimicrob Chemother. 1999 Aug;44(2):163-77.

PMID:
10473223
26.

Cerebral manifestation of Wilson's disease successfully treated with liver transplantation.

Bax RT, Hässler A, Luck W, Hefter H, Krägeloh-Mann I, Neuhaus P, Emmrich P.

Neurology. 1998 Sep;51(3):863-5.

PMID:
9748041
27.

Regulating the use of antibiotics in the community.

Carbon C, Bax RP.

BMJ. 1998 Sep 5;317(7159):663-5. Review. No abstract available.

28.

Clinical trials of antibacterial agents--a commentary.

Finch RG, Bax R.

J Antimicrob Chemother. 1998 Apr;41(4):432-4. No abstract available.

PMID:
9598773
29.

Antibiotic resistance--what can we do?

Bax RP, Anderson R, Crew J, Fletcher P, Johnson T, Kaplan E, Knaus B, Kristinsson K, Malek M, Strandberg L.

Nat Med. 1998 May;4(5):545-6. No abstract available.

PMID:
9585218
30.

Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae.

Abele-Horn M, Busch U, Nitschko H, Jacobs E, Bax R, Pfaff F, Schaffer B, Heesemann J.

J Clin Microbiol. 1998 Feb;36(2):548-51.

31.
32.

Antibiotic resistance: a view from the pharmaceutical industry.

Bax RP.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S151-3.

PMID:
8994797
33.

Growth in the use of antibiotics in the community in England and Scotland in 1980-93.

Davey PG, Bax RP, Newey J, Reeves D, Rutherford D, Slack R, Warren RE, Watt B, Wilson J.

BMJ. 1996 Mar 9;312(7031):613. No abstract available.

34.

[Periodic breathing with periodic oxygen variation in infancy].

von Czettritz G, Bax RT, Eckardt T, Springer S, Emmrich P.

Wien Med Wochenschr. 1996;146(13-14):317-9. German.

PMID:
9012166
35.

Multicenter evaluation of arbitrarily primed PCR for typing of Staphylococcus aureus strains.

van Belkum A, Kluytmans J, van Leeuwen W, Bax R, Quint W, Peters E, Fluit A, Vandenbroucke-Grauls C, van den Brule A, Koeleman H, et al.

J Clin Microbiol. 1995 Jun;33(6):1537-47.

36.

Comparison of four genotyping assays for epidemiological study of methicillin-resistant Staphylococcus aureus.

van Belkum A, Bax R, Prevost G.

Eur J Clin Microbiol Infect Dis. 1994 May;13(5):420-4.

PMID:
8070458
37.

Concordant clonal delineation of methicillin-resistant Staphylococcus aureus by macrorestriction analysis and polymerase chain reaction genome fingerprinting.

Struelens MJ, Bax R, Deplano A, Quint WG, Van Belkum A.

J Clin Microbiol. 1994 Apr;32(4):1134. No abstract available.

38.

[Typing of methicillin-resistant Staphylococcus aureus strains for epidemiological studies using the polymerase chain reaction].

van Belkum A, Bax R, Overbeek BP, Vreede RW, Veringa EM, Quint WG.

Ned Tijdschr Geneeskd. 1993 Nov 20;137(47):2423-7. Dutch.

PMID:
8264832
40.

Comparison of phage typing and DNA fingerprinting by polymerase chain reaction for discrimination of methicillin-resistant Staphylococcus aureus strains.

van Belkum A, Bax R, Peerbooms P, Goessens WH, van Leeuwen N, Quint WG.

J Clin Microbiol. 1993 Apr;31(4):798-803.

41.

Antibiotic treatment and associated prolonged prothrombin time.

Williams KJ, Bax RP, Brown H, Machin SJ.

J Clin Pathol. 1991 Sep;44(9):738-41.

42.
43.

Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe.

Nyström PO, Bax R, Dellinger EP, Dominioni L, Knaus WA, Meakins JL, Ohmann C, Solomkin JS, Wacha H, Wittmann DH.

World J Surg. 1990 Mar-Apr;14(2):148-58. Review.

PMID:
2183477
44.

Conversation piece--the pharmaceutical medicine doctor. Interview by P. D. Welsby.

Bax RP.

Postgrad Med J. 1989 Oct;65(768):799-800. No abstract available.

45.

The pharmacokinetics of meropenem in volunteers.

Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ.

J Antimicrob Chemother. 1989 Sep;24 Suppl A:311-20.

PMID:
2808215
46.

Clinical trials and the pharmaceutical industry.

Bax RP.

J Antimicrob Chemother. 1988 Mar;21(3):278-80. No abstract available.

PMID:
3360690
47.

The development of hypoprothrombinaemia following antibiotic therapy in malnourished patients with low serum vitamin K1 levels.

Cohen H, Scott SD, Mackie IJ, Shearer M, Bax R, Karran SJ, Machin SJ.

Br J Haematol. 1988 Jan;68(1):63-6.

PMID:
3422816
48.

The effects of cefotetan disodium on haemostasis.

Cohen H, Mackie IJ, Walshe K, Shearer M, Bax R, Pozniak A, Moulsdale M, Machin SJ.

J Hosp Infect. 1987 Jul;10(1):51-7.

PMID:
2888812
49.

A multicenter open clinical trial of cefotetan in the treatment of peritonitis.

Mason B, Bax R.

Chemioterapia. 1987 Jun;6(2 Suppl):479-80. No abstract available.

PMID:
3334606
50.

Monotherapy for bacterial peritonitis using cefotetan.

Leaper D, Billings P, Bax R.

Chemioterapia. 1987 Jun;6(2 Suppl):477-8. No abstract available.

PMID:
3334605

Supplemental Content

Support Center